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Toxic effects of available therapeutics are major drawbacks for conventional management approaches in
parasitic infections. Vaccines have provided a promising opportunity to obviate such unwanted com-
plications. In present study, we examined immune augmenting capacities of an emerging adjuvant,
Naltrexone, against Fasciola hepatica infection in BALB/c mice. Seventy BALB/c mice were divided into ﬁve
experimental groups (14 mice per group) including 1- control (received PBS), 2- vaccine (immunized
with F. hepatica E/S antigens), 3- Alum-vaccine (immunized with Alum adjuvant and E/S antigens), 4-
NLT-vaccine (immunized with NLT adjuvant and E/S antigens), and 5- Alum-NLT-vaccine (immunized
with mixed Alum-NLT adjuvant and E/S antigens). Lymphocyte stimulation index was assessed by MTTesearch Center, Basic Health
ciences, Shahrekord, Iran.
aghoobi).
H. Azizi et al. / Experimental Parasitology 189 (2018) 66e71 67assay. Production of IFN-g, IL-4, IgG2a and IgG1 was assessed by ELISA method. Results showed that NLT,
either alone or in combination with alum, can induce immune response toward production of IFN-g and
IgG2a as representatives of Th1 immune response. Also, using this adjuvant in immunization experiment
was associated with signiﬁcantly high proliferative response of splenocytes/lymphocytes. Utilization of
mixed Alum-NLT adjuvant revealed the highest protection rate (73.8%) in challenge test of mice infected
with F. hepatica. These ﬁndings suggest the potential role of NLT as an effective adjuvant in induction of
protective cellular and Th1 immune responses against fasciolosis.
© 2018 Elsevier Inc. All rights reserved.1. Introduction
Fasciolosis is a zoonotic infection caused by Fasciola hepatica and
Fasciola gigantica trematodes. Fasciolosis is an infection primarily
affecting livestock with ﬁnancial and nutritional importance. Due
to the close contact, humans can also be infected by Fasciola spe-
cies. According to the world health organization report, there are
currently 2.4 million affected humans across the globe with 180
million at the risk of the infection (Meemon and Sobhon, 2015).
Therapeutic approaches against fasciolosis have encountered
increasing drug resistance (Rojas-Caraballo et al., 2014). Because of
this, prevention of fasciolosis is a priority for saving funds in both
health care system and food industry. In this regard, vaccination
policies provide a promising strategy.
Efﬁciency of vaccines in promoting a potent immune response
against infections is dependent on a number of features such as
immunogenicity of the antigenic determinants, adjuvant prop-
erties, and administration routes (Chantree et al., 2013). Among
these, the most important may be the capability of adjuvant
compartment to properly modulate immune reactivity. Currently,
there is a shortage in the number of approved adjuvants in
clinical application mainly due to safety concerns. Alum has been
used as an adjuvant for more than seven decades and is currently
in used and approved by Food and Drug Administration (FDA)
agency. This adjuvant, however, acts in favor of T-helper 2 (Th2)
and humoral immune responses and is considered as a desirable
adjuvant against extracellular pathogens (Jazani et al., 2010,
2011). Nevertheless, application of alum in vaccines against
intracellular organisms has been less promising (Harandi et al.,
2010). Therefore, it is advisable to provide alternative adjuvants
with ability to augment the cellular immunity against intracel-
lular organisms.
Vaccination experiments against fasciolosis have been per-
formed using different antigenic and adjuvant determinants.
However, exploiting conventional adjuvants such as Freund's and
alum has been associated with non-protective Th2 immune re-
sponses (Sansri et al., 2015; Changklungmoa et al., 2013).
Naltrexone (NLT) is an opioid antagonist currently used by drug
addicted (Woody, 2014). This prescription drug has a good safety
history and is approved by the FDA for using in humans. In
previous studies, the role of opioid antagonists including NLT has
been noted as a proﬁcient adjuvant in induction of both cellular
and humoral immunities against multiple infections. Specially,
NLT has been highlighted as an appropriate adjuvant against
parasitic infections such as Toxoplasma and Plasmodium species
(Khorshidvand et al., 2016; Tappeh et al., 2013; Shahabi et al.,
2014). Nevertheless, there was no study on the potential role of
NLT as an adjuvant in vaccination against fasciolosis. In present
study, excretory-secretory (E/S) antigens derived from F. hepatica
were used to immunize BALB/c mice along with NLT adjuvant.2. Materials and methods
2.1. Animals
Seventy female BALB/c mice aged 6e8 weeks were prepared
from Razi Vaccine and Serum Research Institute, Karaj, Iran. They
were kept according to the ethical requirements and animal care
instructions announced by Ethical Committee of Zabol University of
Medical Sciences. These mice were assigned to one of ﬁve immu-
nization groups in our study (14mice per group). Five selectedmice
per each group were used for determination of lymphocyte stim-
ulation index, as well as cytokines, and antibody measurements.
Seven mice per group were further subjected to the challenge test.
Twomice per groups that wereweaker than others were spared for
being used in experiments.
2.2. Preparation of metacercariae
F. hepatica eggs were obtained from bile ducts and gallbladder of
naturally infected sheep that were killed with standard procedure
at an abattoir. Before harvesting the eggs, F. hepatica parasites were
characterized based on morphological features (i.e. shorter length,
smaller ventral sucker, and larger cephalic cone) to avoid
misidentiﬁcation as F. gigantica. The eggs were then stimulated to
shed miracidia by dark incubation in 0.85% normal saline for two
weeks, and subsequently illuminated for 2 h. The hatchedmiracidia
were then transferred to Lymnaea truncatulawith twomiracidia per
L.truncatula snail. After 45 days of the infection, cercariae began to
shed from the snails. These were then collected using ﬂoating
cellophane papers. Cercariae then immediately started to transform
to metacercariae which were stored at 4 C until use.
2.3. Obtaining excretory and secretory (E/S) antigens
For this purpose, adult F. hepatica parasites were gathered from
gallbladder of naturally infected sheep. After collection, the or-
ganisms were rinsed in 0.85% normal saline six times to take out
remnants of bile ducts and surrounding tissues. These were then
cultured in RPMI1640 medium containing antibiotics (penicillin
and streptomycin) at 37 C. For obtaining E/S antigens, the medium
was periodically centrifuged every 6 h (15,000 g, 30min, 37 C) for
24 h (Kueakhai et al., 2013). E/S antigens enriched in supernatant
medium were collected. The supernatants were detected by Low-
ry's method (Bio-Rad) to determine the protein concentration.
These antigens were stored at 80 C until use.
2.4. Immunization
Mice were randomly assigned to one of ﬁve immunization
groups (14 per group). These groups included: 1- Control (non-
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(PBS)), 2- Vaccine (mice immunized with 50 ml E/S antigens along
with 100 ml PBS without any adjuvant), 3- Alum-vaccine (immu-
nized with 50 ml volume of each of alum, E/S antigens, and PBS), 4-
NLT-vaccine (immunized with 50 ml volume of each of NLT, E/S
antigens, and PBS), and 5- Alum-NLT-vaccine (immunized with
50 ml of E/S antigens along with 100 ml of Alum-NLT mixed adju-
vant). NLT was administrated at the net concentration of 6mg/kg.
For the preparation of the mixed Alum-NLT adjuvant, we initially
prepared 6mg/ml solution of NLT in 50 ml of PBS, and then the
AlumeNLT mixture was formed by addition of 50 ml alum
(aluminum phosphate gel, Sigma, Germany) to the mixture. (Jazani
et al., 2011; Shahabi et al., 2014; De Gregorio et al., 2008). Immu-
nization was done by intraperitoneally injections at day 0 and 7.2.5. Lymphocyte stimulation index
To assess proliferation response of splenocytes/lymphocytes of
mice immunized with different adjuvants, these cells were har-
vested two weeks following the last immunization. For this pur-
pose, spleens from ﬁve mice per group were recovered after killing
them, and splenocytes were retrieved in a sterile condition using a
wire mesh. The cells were then cultured in RPMI 1640 medium
containing 10% fetal calf serum1 (FCS) (Gibco-BRL), 2mM L-gluta-
mine, and 25mM HEPES.
For stimulation experiment, 100 ml of splenocytes/lymphocytes
suspension was transferred into 96-well plates at a density of
1 106 cells/ml per well. These cells were subsequently encoun-
tered with 10 ml of the E/S antigens (10 mg/ml) for assessing their
proliferation capacity using MTT (3[4,5-dimethylthiazol-2-ml]-2,5-
diphenyltetrazolium bromide; thiazolyl-blue, Sigma, Germany)
assay. The procedure was performed at 72 h post antigen exposure.
Stimulation index of the cells was judged by optical density (OD) of
the wells at 540 nm, and calculated as follows:Stimulation index ¼Mean OD of stimulated cellsMean OD of the Blank
Mean OD of unstimulated cellsFor positive and negative controls, the cells were exposed to
either 5 mg/ml concanavalin A (Sigma), or 10 ml of the culture me-
dium respectively.2.6. Determination of IFN- g and IL-4 levels
To assess Th1 and Th2 immune responses, IFN-g and IL-4 cy-
tokines were measured respectively. This was carried out at two
weeks after the second immunization. Splenocytes and lympho-
cytes were obtained from ﬁve mice (the same mice used for stim-
ulation index determination) and were cultured as mentioned in
the previous section. Medium supernatants were subjected to the
cytokine measurements 72 h following the cell culture. IFN-g and
IL-4 levels were determined by enzyme-linked immunosorbent
assay (ELISA kit, eBscience, USA) according to the manufacturer's
instructions. All experiments were performed in triplicate.1 Fetal calf serum.2.7. Determination of IgG2a and IgG1 levels
Speciﬁc ELISA kits for IgG2a (Mouse IgG2a ELISA Ready-Set-Go,
88-50420) and IgG1 (Mouse IgG1 ELISA Ready-Set-Go, 88-50410)
were purchased from eBioscince. The antibodies levels in the sera
of the mice (the samemice used for stimulation index and cytokine
measurements) were determined at two weeks following the last
immunization.2.8. The protection rate of immunization experiments
Seven mice immunized in each group were orally transfected
with 30metacercariae after twoweeks from the last immunization.
Metacercariae were six-weeks old. After six weeks, challenged
mice were killed and the parasites were enumerated within their
livers. Livers were thoroughly cut into thin tissue segments, and
each segment was carefully sought to identify the parasites. The
existence of the parasites was also inspected in the peritoneal
cavity. Protection rate was calculated as (Changklungmoa et al.,
2016):
Protection (%) ¼ (A B) /A 100
with “A” denotes the mean number of the ﬂuke obtained from the
mice of non-immunized (control group), and “B” denotes the mean
number of ﬂuke identiﬁed in the mice of immunized groups.2.9. Statistical analyses
Statistical procedures were carried out in SPSS software Ver. 21
(Chicago, IL, USA). Normality of data was checked by the Shapiro-
Wilk test. Statistical tests were independent sample student t-
test, and one-way analysis of variance 2 (ANOVA). P-value of less
than 0.05 was considered as statistically signiﬁcant.3. Results
3.1. Lymphocyte proliferation
The highest stimulation index was observed in mice immunized
with either NLT or Alum-NLT adjuvants. Between these two groups,
using the mixed adjuvant was associated with signiﬁcantly higher
stimulation index than NLT alone (P< 0.001). In addition, mice
immunized with Alum adjuvant showed signiﬁcantly higher
stimulatory index respective to either vaccine or control groups
(P< 0.0001). Fig. 1 shows results of stimulation experiment in
different immunization groups.3.2. Cytokine levels
IFN-g and IL-4 levels were assessed as representatives of Th1
and Th2 immune responses respectively. Results indicated that
using combined Alum-NLT adjuvant was the most efﬁcient
approach in induction of IFN- g. Following this, the highest IFN-g2 One-way analysis of variance.
Fig. 3. The concentrations of IgG1 and IgG2a in mice immunized with Alum and
Naltrexone adjuvants. The levels of IgG2a were signiﬁcantly higher in NLT-vaccine
group respective to Alum-vaccine (a). The highest levels of IgG1 were related to
Alum-NLT and Alum adjuvants (b). The IgG2a/IgG1 ratio was signiﬁcantly higher in
mice received NLT or Alum-NLT than other groups (c). Abbreviations; Cont; Control,
Vac; Vaccine, NLT; Naltrexone, AL; Alum.
Fig. 1. Stimulation index in different experimental groups. Mice received NLT either
alone or in combination with Alum showed higher stimulatory index respective to
mice that received Alum or no adjuvant. Abbreviations; Cont; Control, Vac; Vaccine,
NLT; Naltrexone, AL; Alum.
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Alum-vaccine, vaccine, and PBS (Fig. 2a) respectively.
IL-4 production was signiﬁcantly higher in splenocytes of mice
immunized with Alum-vaccine respective to mice immunized with
either NLT-vaccine or Alum-NLT vaccine (P¼ 0.004, and P< 0.001
respectively, Fig. 2b).
The ratio of IFN-g/IL-4 as an indicator of Th1/Th2 balance was
signiﬁcantly higher in Alum-NLT-vaccine group than either NLT-
vaccine (P< 0.001), or Alum-vaccine (P< 0.001). Fig. 2c shows the
IFN-g/IL-4 ratio in different immunized groups.3.3. Antibody levels
Production of parasite speciﬁc antibodies plays a substantial role
in immunity against parasitic infections. Here we observed that
mice immunized with combined Alum-NLT adjuvant showed
signiﬁcantly higher serum levels of IgG2a antibody compared toFig. 2. Induction of T helper immune response in mice immunized with Alum or NLT
adjuvants. Combined Alum-Naltrexone adjuvant induced INF-g production consider-
ably more than other groups (a), while IL-4 production was signiﬁcantly higher in
splenocytes derived from mice immunized with Alum-vaccine (b). The ratio of IFN-g/
IL-4 as an indicator of Th1/Th2 balance was signiﬁcantly higher in Alum-NLT-vaccine
group than other groups (c). Abbreviations; Cont; Control, Vac; Vaccine, NLT;
Naltrexone, AL; Alum.either NLT (P< 0.001) or Alum adjuvants (P< 0.001). Furthermore,
the levels of IgG2a was signiﬁcantly higher in NLT-vaccine group
respective to Alum-vaccine (P< 0.001, Fig. 3 a).
Fig. 3b shows the concertation of IgG1 antibodies in different
immunization groups. The ﬁndings showed that IgG1 levels were
signiﬁcantly higher in all the immunization groups compared to the
control group. Among vaccinated groups, the highest levels of the
antibody were related to Alum-NLT and Alum groups.
The IgG2a/IgG1 ratio as an indicator of the extent of Th1/Th2
immune responses was signiﬁcantly higher in mice received NLT or
Alum-NLT in comparison with those immunized with Alum or E/S
antigens alone (P< 0.001). The difference between NLT and Alum-
NLT groups was not statistically signiﬁcant (P¼ 0.2, Fig. 3c).
3.4. Fluke recovery
Using Alum-NLT adjuvant rendered the highest protection rate
(73.8%) in the challenge test. This is while the protection rate
reached 53.3% and 15.3% in mice received either NLT or Alum ad-
juvants respectively. The lowest mean numbers of worms recov-
ered from liver of mice belonged to Alum-NLT (1.7± 1.3) and NLT
(3.1± 1) groups (Table 1).
4. Discussion
There have been multiple efforts to produce efﬁcient vaccines
against fasciolosis. In present study, the role of NLTalongwith Alum
was assessed in mice vaccinated by E/S antigens of F. hepatica.
Vaccination against fasciolosis has been enrolled with various
antigenic determinants such as cathepsin, Fasciola proteases, fatty
acid-binding proteins, and oxidoreductase enzymes (Sansri et al.,
2015). In present study, we exploited E/S antigens of F. hepatica.
E/S antigens consist of cathepsin proteases as the main constitute
(Yap and Smooker, 2016). Cathepsin proteases participate in a wide
spectrum of activities including migration, invasion, and pathoge-
nicity of Fasciola species (Norbury et al., 2011). Fatty acid binding
protein is another major component of E/S antigens of F. hepatica
which has been shown to suppress the production of inﬂammatory
cytokines by direct interaction with macrophages (Figueroa-
Santiago and Espino, 2014). Therefore, E/S antigens render a po-
tential target for development of vaccines against fasciolosis.
Table 1
Protection rates rendered by different vaccination approaches against F. hepatica.
Groups Number of parasites per mouse Number of parasites (Mean± SD)a Protection (%)
Control 8, 7, 6, 7, 6, 6, 6 6.5± 0.7 e
Vaccine 6, 6, 4, 4, 6, 7, 7 5.7± 1.2 12.3
Alum-Vaccine 8, 6, 4, 6, 7, 3, 5 5.5± 1.7 15.3
Naltrexone-Vaccine 2, 3, 3, 4, 3, 5, 2 3.1± 1 52.3
Alum- Naltrexone -Vaccine 1, 0, 3, 3, 0, 3, 2 1.7± 1.3 73.8
a ; Signiﬁcant difference was observed comparing Alum-Naltrexone group with either Alum-vaccine (P¼ 0.001), vaccine (P< 0.001) or control (P< 0.0001) groups but not
with Naltrexone group (P¼ 0.05).
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mune cells including antigen presenting cells (macrophages and
dendritic cells), and in this way regulate substantial functions of the
immune system (Rodriguez et al., 2015). Generally, such in-
teractions lead to a non-effective humoral Th2 immunity which
help persistence of the infection (Dalton et al., 2013). In present
study, we showed that using NLT adjuvant either alone or in asso-
ciation with Alum resulted in shifting immune response toward
protective Th1 branch represented by higher levels of IFN-g and
IgG2a. IFN-g and IgG2a are produced by antigen speciﬁc lympho-
cytes, and are considered as indirect indicators of Th1 immunity
(Jamali et al., 2007, 2009). In addition, NLT also induced higher
splenocytes/lymphocytes stimulation index. These changes are
indicative of a pronounced cellular immunity against the infection.
In other studies, Alum-NLT adjuvant incorporated along with
toxoplasma gondii lysate antigen resulted in augmenting of cellular
immunity, higher production of IFN-g, and delayed type hyper-
sensitivity response (Khorshidvand et al., 2016). In the recent study,
the highest concentrations of IFN-g was recorded in mice immu-
nized with Alum-NLT adjuvant compared to the mice received
either NLT or Alum adjuvants which was similar to our ﬁndings
(Khorshidvand et al., 2016). Increased ratio of IFN-g/IL-5 was
observed in the T. gondii experiment that highlighted the efﬁciency
of Alum-NLT mixture in promotion of Th1 immune response
(Khorshidvand et al., 2016). This was also the case in our study
which revealed higher IFN-g/IL-4 ratio in mice received either
Alum-NLT or NLT. In another study, Tappeh et al. used Alum-NLT
adjuvant in a vaccine along with E/S antigens of T. gondii (Tappeh
et al., 2013). The results of the recent experiment showed signiﬁ-
cant induction of speciﬁc IgG2a antibodies by using NLT as an
adjuvant (Tappeh et al., 2013) which was in line with our ﬁndings.
Immune induction properties of NLT have also been tested against
Plasmodium berghei infection (Shahabi et al., 2014). The results of
the recent study demonstrated signiﬁcantly higher lymphocyte
proliferation index, and higher IFN-g production in Alum-NLT
received mice in comparison with mice treated with either indi-
vidual NLT or Alum. In line with this, lymphocyte stimulation index
was also the highest in NLT-Alum group in the recent study
(Shahabi et al., 2014). Altogether, these ﬁndings recommend NLT as
a potential and efﬁcient adjuvant against parasitic infections
including fasciolosis.
Naloxone (NLX) is another opioid antagonist that has been
studied as a potential adjuvant in vaccination against various in-
fections. NLX has delivered signiﬁcantly higher production of IgG2a
and IgG1 speciﬁc antibodies against Salmonella typhimurium (Jazani
et al., 2011). In a vaccination effort against HIV, higher lymphocyte
proliferation index was observed in mice vaccinated along with
Alum- NLXmixture (Velashjerdi Farahani et al., 2016). NLX alone or
in combination with Alum also conferred efﬁcient cellular and Th1
immunity in vaccination against human papilloma viruses (Yasaghi
and Mahdavi, 2016). Using NLX as an adjuvant also demonstrated
boosted cellular and humoral immunities with high production of
IFN-g in vaccination against herpes simplex virus type 1 (Jamaliet al., 2007, 2009). Therefore, it seems that opioid antagonists,
either NLT or NLX can exert beneﬁcial effects on immune response
against intracellular pathogens. This highlights the role of opioid
signaling pathways as modulating mechanisms of immune system.
The mechanisms of immunomodulatory functions of opioid
antagonists are not well understood. Induction of Th1 immune
response is critical for activation of cytotoxic lymphocytes and
efﬁcient eradication of intracellular pathogens. NLT may in part
promote its immune regulating activities by induction of the
cytotoxic activity of natural killer cells (Boyadjieva and Sarkar,
2010). NLT also can promote toxic activities of macrophages (Yi
et al., 2016). The effects of opioid receptors on immune responses
may be partly mediated by modulation of CD4þCD25 þ Foxp3þ
regulatory T lymphocytes (Molla Hassan et al., 2009). In a report,
NLX resulted in signiﬁcant elevation of IL-17 immunoregulatory
cytokine (Yasaghi and Mahdavi, 2016). Using NLX has also been
related to higher counts of CD8þ and lower counts of CD4þ lym-
phocytes (Molla Hassan et al., 2009). In an experiment by Meng
et al., NLT induced expression of multiple stimulatory and co-
stimulatory molecules including MHC II, CD40, CD80, and CD86
on antigen presenting dendritic cells (Meng et al., 2013). These
immunoregulatory effects accompanied by induction of lympho-
cytes proliferation and secretion of IL-2 and TNF-a (Meng et al.,
2013). Synergistic effects NLX with other adjuvants on promoting
cellular immunity has been highlighted in vaccination of animal
models against Plasmodium vivax (Someabozorg et al., 2015).
Detailed mechanisms participating in immune modulating activ-
ities of opioid antagonists are to be disclosed in future.
We showed in our experiment that Alum-NLT adjuvant resulted
in the highest protection rate (73.8%) against F. hepatica infection.
This is while NLT or Alum alone only resulted in 52.3% and 15.3%
protection rates respectively. In comparison, mice immunized with
Alum-NLT mixture showed signiﬁcantly higher survival rate in
challenge test against T. gondii (Khorshidvand et al., 2016). Vacci-
nation experiments using NLX rendered signiﬁcant protections
against herpes simplex virus type 1 in mice (Jamali et al., 2007,
2009). In challenge test against Salmonella typhimurium, mice
received Alum-NLX adjuvant were showed signiﬁcantly lower
bacterial load in their spleens and livers compared to the mice
treated with either NLX or Alum alone (Jazani et al., 2011). The
higher protection rates may be partly related to the induction of
proliferative, cytotoxic and IFN-g producing activities of lympho-
cytes by opioid antagonists (Velashjerdi Farahani et al., 2016). Ev-
idences are emerging that accentuate the role of antigenic epitopes
in inﬂuencing protection rates in mice vaccinated against fas-
ciolosis (Rojas-Caraballo et al., 2014). Using F. gigantica derived
Leucine aminopeptidase as antigenic determinants along with
Freund's adjuvant resulted in signiﬁcant protection rate (60.8%).
(Changklungmoa et al., 2013). Similar results were produced by
vaccination with cathepsin L as the antigenic peptide which
delivered protection rate of 62.7% (Sansri et al., 2015). It seems that
protection against infections is dependent on both adjuvant and
antigenic peptides.
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NLT, either individually or in combination with Alum, can be an
efﬁcient adjuvant for induction of Th1 and cellular immunity re-
sponses against F. hepatica infection. In accordance, NLT can dedi-
cate signiﬁcant protection against the infection in immunizedmice.
NLT can serve as a potential adjuvant in vaccine production efforts
against fasciolosis.
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